Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2007

01-12-2007 | Gastrointestinal Oncology

Clinical and Prognostic Significance of RhoA and RhoC Gene Expression in Esophageal Squamous Cell Carcinoma

Authors: Ahmad Faried, MD, PhD, Leri S. Faried, MD, Nurhayat Usman, MD, Hiroyuki Kato, MD, PhD, Hiroyuki Kuwano, MD, PhD

Published in: Annals of Surgical Oncology | Issue 12/2007

Login to get access

Abstract

Background

Rho GTPases are involved in the organization of a microfilament network, cell-to-cell interaction, and malignant transformation. To elucidate the role of Rho GTPases in esophageal squamous cell carcinoma (ESCC), we compared the levels of RhoA and RhoC mRNA from ESCC with the corresponding normal tissue originating from the same patients.

Methods

Real-time reverse transcriptase–polymerase chain reaction was performed to observe rhoA and rhoC in esophageal cell lines. Next, the mRNA levels of rhoA and rhoC were evaluated from 50 patients.

Results

The rhoA and rhoC were higher in ESCC cell lines than in noncancerous esophageal cell. rhoC was overexpressed in TTn, which was obtained directly from a surgical specimen of a metastatic lesion of ESCC in the mandible. rhoA and rhoC were significantly higher in ESCC patient than in the normal counterparts (P = .0022 and P < .0001, respectively). rhoA correlated with tumor differentiation and rhoC correlated with an advanced tumor, node, metastasis system classifications. rhoA and rhoC in ESCC showed a positive correlation (P = .008). Patients with rhoA overexpression showed a significantly poorer prognosis than those with rhoA underexpression (P = .044).

Conclusions

To our knowledge, this study is the first in which the expression of RhoA and RhoC at the mRNA level in ESCC was examined and compared with its normal counterpart. Our results suggest that rhoA and rhoC are involved in ESCC progression and useful as prognostic markers. Further study will be needed to examine the therapeutic potential of the Rho GTPase inhibitor as a promising anticancer therapy, especially in ESCC.
Literature
1.
Berrino F, Sant M, Verdecchia A, et al., eds. Survival of Cancer Patients in Europe: The EUROCARE Study. IARC Scientific Publication No. 132. Lyon, France: IARC 1995
2.
Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462–7PubMedCrossRef
3.
Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305–13PubMed
4.
5.
del Peso L, Hernandez-Alcoceba R, Embade N, et al. Rho proteins induce metastatic property in vivo. Oncogene 1997;15:3047–57PubMedCrossRef
6.
Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999;81:682–7PubMedCrossRef
7.
Horiuchi A, Imai T, Wang C, et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003;83:861–70PubMed
8.
Kamai T, Tsujii T, Arai K, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003;9:2632–41PubMed
9.
Faried A, Nakajima M, Sohda M, Miyazaki T, Kato H, Kuwano H. Correlation between RhoA overexpression and tumor progression in esophageal squamous cell carcinoma. Eur J Surg Oncol 2005;31:410–4PubMedCrossRef
10.
Li XR, Ji F, Ouyang J, Wu W, Qian LY, Yang KY. Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma. Eur J Surg Oncol 2006;32:1130–4PubMedCrossRef
11.
Kamai T, Arai K, Tsujii M, Honda M, Yoshida K. Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU Int 2001;87:227–31PubMedCrossRef
12.
Kleer CG, van Golen KL, Zhang Y, et al. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002;160:579–84PubMed
13.
Kleer CG, Griffith KA, Sabel MS, et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinoma of the breast. Breast Cancer Res Treat 2005;93:101–10PubMedCrossRef
14.
Kleer CG, Teknos TN, Islam M, et al. RhoC GTPase as a potential marker of lymph node metastasis in squamous cell carcinoma of the head and neck. Clin Cancer Res 2006;12:4485–90PubMedCrossRef
15.
Suwa H, Ohshio G, Imamura T, et al. Overexpression of the rhoC gene correlates with the progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998;77:147–52PubMed
16.
Wang W, Yang LY, Huang, et al. Genomic analysis revels RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 2004;90:2349–55PubMed
17.
Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406:532–5PubMedCrossRef
18.
van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000;60:5832–8PubMed
19.
Faried A, Faried LS, Kimura H, et al. RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo. Eur J Cancer 2006;42:1455–65PubMedCrossRef
20.
Sobin LH, Wittekind C, eds. TNM: Classification of Malignant Tumours. 6th ed. New York: Wiley, 2002
21.
Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 1993;119:441–9PubMedCrossRef
22.
Takahashi K, Kanazawa H, Chan H, Hosono T, Takahara M, Saito K. A case of esophageal carcinoma metastatic to the mandible and characterization of two cell lines (TT and TTn) established from the oral tumor. Jpn J Oral Maxillofac Surg 1990;36:307–16
23.
Sashiyama H, Shino Y, Sakao S, et al. Alteration of integrin expression rates to malignant progression of human papillomavirus-immortalized esophageal keratinocytes. Cancer Lett 2002;177:21–8PubMedCrossRef
24.
Xu M, Miller MS. Determination of murine fetal reverse transcriptase–polymerase chain reaction. Toxicol Appl Pharmacol 2004;201:295–302PubMedCrossRef
25.
R statistical software. Available at: ftp://ftp.u-aizu.ac.jp/pub/lang/R/CRAN/
26.
Zhou J, Zhao LQ, Xiong MM, et al. Gene expression profiles at different stages of human esophageal squamous cell carcinoma. World J Gastroenterol 2003;9:9–15PubMed
27.
Lawler K, Foran E, O’Sullivan G, Long A, Kenny D. Mobility and invasiveness of metastatic esophageal cancer are potentiated by shear stress in a ROCK- and Ras-dependent manner. Am J Physiol Cell Physiol 2006;291:C668–77PubMedCrossRef
28.
Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241–69PubMedCrossRef
29.
Adamson P, Marshall CJ, Hall A, Tilbrook PA. Post-translational modifications of p21rho proteins. J Biol Chem 1992;267:20033–8PubMed
30.
van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyltransferase inhibitor. Mol Cancer Ther 2002;1:575–83PubMed
31.
Collisson EA, Kleer C, Wu M, et al. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2003;2:941–8PubMed
32.
Tang D, Park HJ, Georgescu SP, Sebti SM, Hamilton AD, Galper JB. Simvastatin potentiates tumor necrosis factor alpha–mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA. Life Sci 2006;79:1484–92PubMedCrossRef
33.
Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma: a randomized controlled trial. Br J Cancer 2001;84:886–91PubMedCrossRef
34.
Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999;5:221–5PubMedCrossRef
35.
Imamura F, Mukai M, Ayaki M, Akedo H. Y-27632, an inhibitor of Rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn J Cancer Res 2000;91:811–6PubMed
36.
Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 2000;269:652–9PubMedCrossRef
Metadata
Title
Clinical and Prognostic Significance of RhoA and RhoC Gene Expression in Esophageal Squamous Cell Carcinoma
Authors
Ahmad Faried, MD, PhD
Leri S. Faried, MD
Nurhayat Usman, MD
Hiroyuki Kato, MD, PhD
Hiroyuki Kuwano, MD, PhD
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9562-x

Other articles of this Issue 12/2007

Annals of Surgical Oncology 12/2007 Go to the issue

OriginalPaper

Impact of Adjuvant Radiation on Survival: A Note of Caution When Using Cancer Registry Data to Evaluate Adjuvant Treatments

Breast Oncology

Breast MRI Wire-Guided Excisional Biopsy: Specimen Size as Compared to Mammogram Wire-Guided Excisional Biopsy and Implications for Use

Bone and Soft Tissue Sarcomas

Epithelioid Sarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution

Gastrointestinal Oncology

Reduced Expression of Apaf-1 in Colorectal Adenocarcinoma Correlates with Tumor Progression and Aggressive Phenotype

Editorial

Editorial on “Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis”

Hepatic and Pancreatic Tumors

Preoperative Portal Vein Embolization and Surgical Resection in Patients with Hepatocellular Carcinoma and Small Future Liver Remnant Volume: Comparison with Transarterial Chemoembolization